Search This Blog

Wednesday, May 14, 2025

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital

 Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.

Shareholders may elect to receive either the new offer or the previous offer of $3 per share, with an additional $6.84 contingent upon bluebird achieving certain sales milestones.

https://finance.yahoo.com/news/bluebird-bio-receives-higher-upfront-125148001.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.